Acute Postoperative Pain — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for acute postoperative pain. 324 active patents protecting 7 drugs from 7+ originators. First major cliff: 2030. Daily refresh.

7
Approved drugs
324
Active US patents
57/100
Avg vulnerability
$1.6B
Annual revenue covered

Originators in Acute Postoperative Pain

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Indivior 96 patents Purdue Pharma Lp 79 patents Johnson & Johnson (Janssen Pharmaceutica) 68 patents Purdue Pharma 40 patents Generic (originally Boots Group) 14 patents Fresenius Kabi 14 patents Pfizer Inc. (originally Searle/Pharmacia) 13 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating acute postoperative pain. Each bar = one year. Y-axis scaled to peak year (104 patents).

7
26
87
27
5
28
16
29
47
30
17
31
104
32
7
34
7
35
26
36
1
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Subutex
Buprenorphine Hydrochloride
 Indivior 96 62 $800M 2027-07-23
Subutex
BUPRENORPHINE
 Purdue Pharma Lp 79 71 $800M 2026-07-31
Duragesic
fentanyl
 Johnson & Johnson (Janssen Pharmaceutica) 68 51 — 2027-01-25
OxyContin
oxycodone
 Purdue Pharma 40 51 — 2028-10-09
Dilaudid-Hp
Hydromorphone Hydrochloride
 Fresenius Kabi 14 46 — 2032-04-23
Advil
ibuprofen
 Generic (originally Boots Group) 14 70 — 2029-09-30
Celebrex
celecoxib
 Pfizer Inc. (originally Searle/Pharmacia) 13 51 — 2030-04-19

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236755 Subutex method of use 88 2026-07-31
8236292 Subutex method of use 88 2027-01-10
8236292 Subutex method of use 88 2027-01-10
8236292 Subutex method of use 88 2027-01-10

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10245276 Celebrex composition of matter 10 2030-04-19
8598152 Celebrex composition of matter 10 2030-04-19
9012440 Celebrex composition of matter 10 2030-04-19
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27

Related